Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin pegylated liposomal
- Development stage
- Preclinical
- Lead developer
- LEAF Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
LEAF-1404 is a complex generic version of pegylated liposomal doxorubicin (originally marketed as Caelyx/Doxil). Developed by LEAF Pharmaceuticals and manufactured by its subsidiary LEAF Rwanda, LEAF-1404 is designed to treat ovarian cancer, breast cancer, and AIDS-related Kaposi's sarcoma. The formulation consists of doxorubicin hydrochloride encapsulated within polyethylene glycol (PEG)-coated liposomes, which alters the drug's pharmacokinetics by prolonging circulation time and reducing cardiotoxicity compared to conventional doxorubicin. Once released, doxorubicin acts as an anthracycline topoisomerase II inhibitor and DNA intercalator, disrupting DNA replication and transcription to induce cancer cell death.
- Other names
- doxorubicin hydrochloride liposomepegylated liposomal doxorubicinpegylated liposomal doxorubicin hydrochloride
02
Targets
ATM (Ataxia telangiectasia mutated protein)CHEK1 (Checkpoint kinase 1)CHEK2 (Checkpoint kinase 2)DNATOP1 (DNA Topoisomerase I)TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin pegylated liposomal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin pegylated liposomal.